Unapproved New Drug

A drug is anything intended for the diagnosis, cure, mitigation, treatment or prevention of disease, or to affect the structure or any function of the body. A new drug is one not generally recognised among qualified experts as safe and effective for its labelled use, and general recognition requires published, well-controlled evidence plus expert consensus. Marketing one without an approved application violates the Act, and the product is usually misbranded too, since only approved products escape the requirement to bear adequate directions for lay use.

Intended use is where most peptide sellers are caught, and it is deliberately not confined to the label. The regulations let the agency read intent from labelling, advertising, statements by the firm or its representatives, and the circumstances of distribution. A 2021 rulemaking kept that broad evidentiary approach, and FDA's separate initiative on long-marketed unapproved products has been withdrawn and restored in recent years, so the current enforcement posture should be checked rather than assumed.

This is the classification most grey-market peptides actually occupy, and naming it correctly matters: it is not a gap in the rules but a defined violation, which is why enforcement reaches sellers through warning letters, import detention, seizure and injunction. It also explains what is missing, namely no approved labelling, no adverse event reporting duty and no recall mechanism.

The disclaimers built to evade this rarely work. Research use only and not for human consumption do not defeat intended use when the seller's own site describes human administration, because circumstances of distribution are themselves evidence. The mirror error infers that an unapproved compound was examined and rejected; most were never submitted, a different and far less informative fact.